Your browser doesn't support javascript.
loading
High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors.
Spiegler, Stefanie; Najm, Juliane; Liu, Jian; Gkalympoudis, Stephanie; Schröder, Winnie; Borck, Guntram; Brockmann, Knut; Elbracht, Miriam; Fauth, Christine; Ferbert, Andreas; Freudenberg, Leonie; Grasshoff, Ute; Hellenbroich, Yorck; Henn, Wolfram; Hoffjan, Sabine; Hüning, Irina; Korenke, G Christoph; Kroisel, Peter M; Kunstmann, Erdmute; Mair, Martina; Munk-Schulenburg, Susanne; Nikoubashman, Omid; Pauli, Silke; Rudnik-Schöneborn, Sabine; Sudholt, Irene; Sure, Ulrich; Tinschert, Sigrid; Wiednig, Michaela; Zoll, Barbara; Ginsberg, Mark H; Felbor, Ute.
Afiliación
  • Spiegler S; Department of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald Greifswald, Germany.
  • Najm J; Department of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald Greifswald, Germany.
  • Liu J; Department of Medicine, University of California San Diego San Diego, California.
  • Gkalympoudis S; Department of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald Greifswald, Germany.
  • Schröder W; Department of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald Greifswald, Germany.
  • Borck G; Institute of Human Genetics, University of Ulm Ulm, Germany.
  • Brockmann K; Department of Paediatrics and Paediatric Neurology, University of Göttingen Göttingen, Germany.
  • Elbracht M; Institute of Human Genetics, University of Aachen Aachen, Germany.
  • Fauth C; Division of Human Genetics, Medical University Innsbruck Innsbruck, Austria.
  • Ferbert A; Department of Neurology, Klinikum Kassel GmbH Kassel, Germany.
  • Freudenberg L; Department of Neuropaediatrics, University Hospital Dresden Dresden, Germany.
  • Grasshoff U; Institute of Medical Genetics and Applied Genomics, Rare Disease Center Tübingen, University of Tübingen Tübingen, Germany.
  • Hellenbroich Y; Institute of Human Genetics, University of Lübeck Lübeck, Germany.
  • Henn W; Department of Human Genetics, Saarland University Homburg/Saar, Germany.
  • Hoffjan S; Department of Human Genetics, Ruhr-University Bochum, Germany.
  • Hüning I; Institute of Human Genetics, University of Lübeck Lübeck, Germany.
  • Korenke GC; Department of Neuropaediatrics, Children's Hospital Oldenburg, Germany.
  • Kroisel PM; Institute of Human Genetics, Medical University Graz Graz, Austria.
  • Kunstmann E; Institute of Human Genetics, University of Würzburg Würzburg, Germany.
  • Mair M; Department of Human Genetics, Saarland University Homburg/Saar, Germany.
  • Munk-Schulenburg S; Institute of Human Genetics, University of Freiburg Freiburg, Germany.
  • Nikoubashman O; Department for Interventional and Diagnostic Neuroradiology, University Hospital Aachen Aachen, Germany.
  • Pauli S; Institute of Human Genetics, University of Göttingen Göttingen, Germany.
  • Rudnik-Schöneborn S; Institute of Human Genetics, University of Aachen Aachen, Germany.
  • Sudholt I; Institute of Medical Genetics, University of Zürich Zürich, Switzerland.
  • Sure U; Department of Neurosurgery, University Hospital Essen Essen, Germany.
  • Tinschert S; Institute of Clinical Genetics, Technical University of Dresden Dresden, Germany.
  • Wiednig M; Department of Environmental Dermatology and Venereology, Medical University Graz Graz, Austria.
  • Zoll B; Institute of Human Genetics, University of Göttingen Göttingen, Germany.
  • Ginsberg MH; Department of Medicine, University of California San Diego San Diego, California.
  • Felbor U; Department of Human Genetics, University Medicine Greifswald and Interfaculty Institute of Genetics and Functional Genomics, University of Greifswald Greifswald, Germany.
Mol Genet Genomic Med ; 2(2): 176-85, 2014 Mar.
Article en En | MEDLINE | ID: mdl-24689081
ABSTRACT
Cerebral cavernous malformations (CCM) are prevalent vascular malformations occurring in familial autosomal dominantly inherited or isolated forms. Once CCM are diagnosed by magnetic resonance imaging, the indication for genetic testing requires either a positive family history of cavernous lesions or clinical symptoms such as chronic headaches, epilepsy, neurological deficits, and hemorrhagic stroke or the occurrence of multiple lesions in an isolated case. Following these inclusion criteria, the mutation detection rates in a consecutive series of 105 probands were 87% for familial and 57% for isolated cases. Thirty-one novel mutations were identified with a slight shift towards proportionally more CCM3 mutations carriers than previously published (CCM1 60%, CCM2 18%, CCM3 22%). In-frame deletions and exonic missense variants requiring functional analyses to establish their pathogenicity were rare An in-frame deletion within the C-terminal FERM domain of CCM1 resulted in decreased protein expression and impaired binding to the transmembrane protein heart of glass (HEG1). Notably, 20% of index cases carrying a CCM mutation were below age 10 and 33% below age 18 when referred for genetic testing. Since fulminant disease courses during the first years of life were observed in CCM1 and CCM3 mutation carriers, predictive testing of minor siblings became an issue.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Mol Genet Genomic Med Año: 2014 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Mol Genet Genomic Med Año: 2014 Tipo del documento: Article País de afiliación: Alemania